ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

US Oncology Renegotiates Agreements To Operate Under Net Earnings Model.

March 30, 2001

Amgen Cancels Rilotumumab Trials in Gastric Cancer

December 26, 2014

Dingell: “Unable To Vouch” For Staff Report On NCI’s Gallo

February 10, 1995

In Brief: Columbia University Double Lab Space; GM Cancer Awards to Suit, Folkman, Nurse

June 6, 1997

DCT board Oks New Cooperative Groups For MRI Evaluations In Breast Cancer

February 18, 1994

Liver Transplants Extend Survival In Early-Stage Cancer

January 27, 2006